LDC Supervisors

Dr. Uwe Koch, Computational Chemist at LDC, obtained his doctoral degree in chemistry at the University of Frankfurt (1993). Subsequently he moved for almost 3 years to Cambridge University (UK) to work in structural bioinformatics. In 1997 he started at Merck, Sharp & Dohme as a computational chemist. In 2004 Uwe became responsible for Bio- and Cheminformatics as well as the NMR group at the MSD site in Rome (It) where he participated in the discovery of Isentress and several clinical candidates such MK-3281 and MK-5172. Uwe is a co-inventor of 15 patents and a co-author of 53 publications. In 2009 he moved to the LDC as a computational chemist.

Dr. Peter NussbaumerDr. Peter Nussbaumer, CEO and Head of Chemistry at LDC, graduated at the Vienna University of Technology, Austria, in organic chemistry and received his doctoral degree in 1985 from the same university. He joined Novartis (Sandoz) as a postdoctoral fellow and became laboratory head there in 1987. After responsibilities as group leader in medicinal chemistry and interdisciplinary program team leader, Peter was appointed Executive Director in 2002 heading the Chemistry Unit of the Novartis Institutes for BioMedical Research in Vienna. In 1999 he received the Novartis Leading Scientist Award. In 2008 Peter moved to Dortmund and joined LDC as Managing Director & Head of Medicinal Chemistry. He is (co)author of 20 patents and 63 peer-reviewed publications, member of the International Advisory Board of ChemMedChem as well as member of the External Scientific Advisory Board of the “MolTagProgramme” (Vienna) and the “Experimental Therapeutics Programme” of the CNIO (Madrid).

Dr. KleblDr. Bert Klebl, CEO & CSO at LDC, has gathered more than 15 years of professional experience in the life sciences/pharmaceutical industry. He has worked in different positions in drug discovery and early development. He is in his current role at LDC since early 2008. Most recently he was Senior Director Discovery Biology and Head of Biology at GPC Biotech. Previously he was Axxima’s Vice President Research and as such responsible for the discovery and development of the company’s portfolio of kinase inhibitors for various therapeutic indications. In former positions, he has worked as a project and platform manager primarily on a kinase inhibitor program, as well as a scientist at Aventis and Hoechst Marion Roussel. He earned his PhD in biochemistry at the University of Konstanz, Germany, and did postdoctoral work at the NRC Biotechnology Research Institute in Montréal, Canada. In the course of his research, he has published more than 30 articles in peer-reviewed journals and is a co-inventor of more than 20 patents and patent applications. He is scientific advisory board member of CI3, EMD and Vichem Kft. In addition he served as an expert panel reviewer for translation research centers, e.g. CDRD, Vancouver/Canada and IP-K, Seoul/South Korea.